Amid a climate of shifting global economic indicators and mixed market reactions, the Swedish stock exchange presents unique opportunities for investors seeking value. As inflation rates and monetary policies influence international markets, discerning investors might find undervalued stocks particularly appealing in the current environment. Top 10 Undervalued Stocks Based On Cash Flows In Sweden Name Current Price Fair Value (Est) Discount (Est) RVRC Holding (OM:RVRC) SEK44.62 SEK86.94 48.7% Gränges (OM:GRNG) SEK136.10 SEK258.03 47.3% Afry (OM:AFRY) SEK202.80 SEK394.51 48.6% Nolato (OM:NOLA B) SEK60.55 SEK115.75 47.7% Stille (OM:STIL) SEK210.00 SEK395.81 46.9% Dometic Group (OM:DOM) SEK70.25 SEK130.36 46.1% Biotage (OM:BIOT) SEK171.20 SEK317.08 46% Sinch (OM:SINCH) SEK23.32 SEK43.53 46.4% Hexatronic Group (OM:HTRO) SEK57.12 SEK106.52 46.4% Image Systems (OM:IS) SEK1.50 SEK2.85 47.3% Click here to see the full list of 47 stocks from our Undervalued Swedish Stocks Based On Cash Flows screener. Let's explore several standout options from the results in the screener. Fortnox Overview: Fortnox AB operates in providing financial and administrative software solutions to small and medium-sized businesses, accounting firms, and organizations, with a market capitalization of approximately SEK 39.31 billion. Operations: Fortnox generates revenue from several key areas: Core Products at SEK 734 million, Businesses at SEK 378 million, Accounting Firms at SEK 352 million, Financial Services at SEK 249 million, and Marketplaces at SEK 160 million. Estimated Discount To Fair Value: 15.7% Fortnox, priced at SEK 64.44, is positioned below its estimated fair value of SEK 76.46, reflecting a potential undervaluation in the Swedish market. The company's recent financials show robust growth with second-quarter revenue reaching SEK 521 million, up from SEK 413 million year-over-year, and net income increasing to SEK 164 million from SEK 127 million. Forecasts suggest a substantial earnings growth of approximately 21.8% annually over the next three years, outpacing the broader market expectations and indicating an attractive cash flow scenario for investors considering undervalued stocks based on these metrics. Upon reviewing our latest growth report, Fortnox's projected financial performance appears quite optimistic. Click here to discover the nuances of Fortnox with our detailed financial health report. OM:FNOX Discounted Cash Flow as at Jul 2024 Lime Technologies Overview: Lime Technologies AB specializes in providing SaaS-based customer relationship management (CRM) solutions primarily in the Nordic region, with a market capitalization of SEK 4.85 billion. Operations: The company generates revenue primarily through the sale and implementation of CRM systems, totaling SEK 631.84 million. Estimated Discount To Fair Value: 15.3% Lime Technologies, trading at SEK 365, is below its estimated fair value of SEK 431.04, suggesting a mild undervaluation. The company has demonstrated consistent financial growth with earnings increasing by 15.9% annually over the past five years and revenue projected to grow at 14.6% per year. Despite high debt levels, Lime's robust forecasted earnings growth of 24.4% annually could appeal to investors looking for cash flow-based undervalued stocks in Sweden. In light of our recent growth report, it seems possible that Lime Technologies' financial performance will exceed current levels. Delve into the full analysis health report here for a deeper understanding of Lime Technologies. OM:LIME Discounted Cash Flow as at Jul 2024 Xvivo Perfusion Overview: Xvivo Perfusion AB is a medical technology company based in Sweden, specializing in machines and solutions for organ assessment and preservation before transplantation, operating globally with a market cap of SEK 16.06 billion. Operations: Xvivo Perfusion generates revenue through three primary segments: Services at SEK 83.39 million, Thoracic at SEK 451.49 million, and Abdominal at SEK 163.85 million. Estimated Discount To Fair Value: 24.4% Xvivo Perfusion, priced at SEK 510, is observed to be significantly undervalued with a fair value estimate of SEK 674.75. Recent earnings reports show robust growth with sales reaching SEK 396.37 million in the first half of 2024, marking a substantial year-over-year increase. Expected to outpace the Swedish market, Xvivo's revenue and earnings are forecasted to grow by 24.3% and 37.83% annually respectively over the next three years. However, concerns include shareholder dilution over the past year and a highly volatile share price recently. Our comprehensive growth report raises the possibility that Xvivo Perfusion is poised for substantial financial growth. Unlock comprehensive insights into our analysis of Xvivo Perfusion stock in this financial health report. OM:XVIVO Discounted Cash Flow as at Jul 2024 Taking Advantage Explore the 47 names from our Undervalued Swedish Stocks Based On Cash Flows screener here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Interested In Other Possibilities? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include OM:FNOXOM:LIMEOM:XVIVO and Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
Exploring Undervalued Stocks On The Swedish Exchange With Discounts Ranging From 15.3% To 24.4%
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...